Clozaril superiority claim?

30 Sep 2002
News

Executive Summary

FDA's Psychopharmacologic Drugs Advisory Committee will review Novartis'Clozaril (clozapine) for treatment of suicidality in patients with schizophrenia or schizoaffective disorders Nov. 4. The review will focus on a head-to-head study versus Lilly's Zyprexa (olanzapine). The meeting will take place at the Holiday Inn, Gaithersburg, Md. [To sign up for a webcast of this meeting, visit 1FDAAdvisoryCommittee.com.]...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS040536

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS040536

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Clozaril superiority claim?

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert